Rheumatology – Medxy AI

Intra-articular Hyaluronic Acid Injections: Long-Term Benefits in Early-Stage Knee Osteoarthritis and Older Women

By MedXY 11/04/2025

Systematic review of 71 RCTs reveals that intra-articular hyaluronic acid injections offer initial symptom worsening but significant long-term relief, especially in early-stage knee osteoarthritis and older women; molecular weight’s role requires further study.

news Rheumatology

GZMK+ CD8+ T Cells Drive Selective Acinar Cell Loss and Interferon Signaling in Sjögren’s Disease

By MedXY 11/04/2025

Single-cell and spatial multi-omics reveal loss of a PRR4⁺CST3⁺ seromucous acinar population and accumulation of GZMK⁺CD8⁺ T cells that induce IFN-driven epithelial dysfunction in Sjögren’s disease.

Neurology news Rheumatology

Outcomes of Maintenance Immunotherapy in Susac Syndrome

By MedXY 11/02/2025

This case series evaluates relapse rates associated with various maintenance immunotherapies in 54 patients with Susac syndrome, highlighting treatment efficacy and challenges in managing this rare autoimmune disorder.

news Orthopedics Rheumatology

Partitioning Knee Osteoarthritis Genetic Risk by BMI Association Clarifies Prediction and Mechanisms

By MedXY 11/02/2025

Partitioning a knee osteoarthritis polygenic score into BMI-associated and BMI-independent components clarifies genetic contributions, improves interpretability, and offers a path to tailored prediction and prevention.

news Orthopedics Rheumatology

Targeting Modifiable Risks to Prevent Knee Osteoarthritis

By MedXY 11/01/2025

A large systematic review identified prior knee injury, older age, and high bone mineral density as predictors of incident radiographic knee osteoarthritis; overweight/obesity and prior injury explained ~14% of cases—highlighting prevention priorities across the life course.

news Orthopedics Rheumatology

Physical Activity and Risk of Knee Replacement in Radiographic Osteoarthritis

By MedXY 11/01/2025

In a 9-year OAI cohort analysis, baseline self-reported moderate physical activity was linked to lower knee replacement risk in KL grade 2 but to higher risk in KL >2; high activity showed no clear effect. Results support severity-tailored activity advice and highlight limitations of single self-report measures.

news Orthopedics Rheumatology

Baseline Sarcopenia Predicts Faster Knee Osteoarthritis Progression and Much Higher Risk of Knee Replacement

By MedXY 11/01/2025

In a longitudinal analysis of 4,316 Osteoarthritis Initiative participants, baseline sarcopenia screened by SARC-F and chair-stand testing was associated with accelerated radiographic and symptomatic knee OA progression over 24–48 months and substantially higher risk of subsequent knee replacement.

news Orthopedics Rheumatology

Chondrocalcinosis Predicts Incident Knee Osteoarthritis

By MedXY 11/01/2025

Two large longitudinal cohorts show baseline chondrocalcinosis is associated with ~75% higher odds of developing radiographic knee osteoarthritis over long-term follow-up, suggesting calcium crystal deposition may be a contributing factor in OA pathogenesis.

Diabetes & Endocrinology news Rheumatology

SGLT-2 Inhibitors and Autoimmune Rheumatic Disease Risk Reduction in Type 2 Diabetes: Insights from a Korean Nationwide Cohort

By MedXY 10/31/2025

A large South Korean cohort study suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the incidence of autoimmune rheumatic diseases by 11% compared to sulfonylureas in adults with type 2 diabetes, indicating potential immunomodulatory benefits of SGLT-2 inhibitors beyond glycemic control.

Nephrology news Rheumatology

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial

By MedXY 10/30/2025

This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors' bone safety in this population.

news Respiratory Rheumatology

Dual αvβ6 and αvβ1 Integrin Inhibition Reduces Lung Collagen Deposition in Idiopathic Pulmonary Fibrosis: Insights from a Phase 2 Clinical Trial

By MedXY 10/28/2025

This phase 2 trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, significantly reduces active type I collagen deposition in IPF lungs, indicating antifibrotic potential and favorable lung remodeling over 12 weeks.

Internal Medicine news Rheumatology

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

By MedXY 10/25/2025

This article reviews a pivotal phase 3 trial demonstrating telitacicept's efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.

Nephrology news Rheumatology

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

By MedXY 10/24/2025

The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis management.

Nephrology news Rheumatology

Avacopan in Older Adults with ANCA-Associated Vasculitis: Efficacy and Safety Confirmed in ADVOCATE Post Hoc Analysis

By MedXY 10/23/2025

This post hoc analysis of the ADVOCATE trial demonstrates that avacopan is effective and safe for treating ANCA-associated vasculitis in patients aged 65 and older, achieving sustained remission with reduced glucocorticoid exposure and toxicity compared to prednisone taper.

Nephrology news Rheumatology

Avacopan Combined with Cyclophosphamide in ANCA-Associated Vasculitis: A Safer and Effective Alternative to Prednisone Taper

By MedXY 10/23/2025

Avacopan, a complement C5a receptor inhibitor, shows comparable remission rates to prednisone taper in ANCA-associated vasculitis patients receiving cyclophosphamide, with benefits of lower relapse, improved kidney function, and reduced glucocorticoid toxicity.

Nephrology news Rheumatology

Real-World Effectiveness of Rituximab and Cyclophosphamide in Severe ANCA-Associated Vasculitis: Insights from J-CANVAS

By MedXY 10/23/2025

A comprehensive review of a Japanese cohort study assessing rituximab and cyclophosphamide efficacy in severe microscopic polyangiitis and GPA, highlighting clinical implications.

news Respiratory Rheumatology

Unveiling Early Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors and Validation of Screening Approaches in the SAIL-RA Cohort

By MedXY 10/19/2025

This article examines the prevalence, risk factors, and diagnostic screening strategies for rheumatoid arthritis-associated interstitial lung disease (RA-ILD) in early rheumatoid arthritis, highlighting age and disease activity as key predictors and validating practical screening tools.

Hematology-Oncology news Rheumatology

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

By MedXY 10/14/2025

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use and need for prospective trials.

Hematology-Oncology news Rheumatology

UBA6: A Novel Therapeutic Vulnerability in VEXAS Syndrome Unveiled by E1 Enzyme Dependency Profiling

By MedXY 10/14/2025

This study characterizes UBA1 mutation effects in VEXAS syndrome and identifies UBA6 as a compensatory enzyme and promising therapeutic target, highlighting selective inhibition to combat mutant hematopoietic clones.

Hematology-Oncology Rheumatology Specialties

VEXAS Anemia: Unraveling the Mosaic Erythroblastopenia in a Novel Autoinflammatory Syndrome

By MedXY 10/14/2025

This study reveals that VEXAS syndrome-associated anemia results from a mosaic erythroblastopenia due to selective UBA1 mutations in early erythroid precursors, advancing understanding of its pathophysiology and therapeutic implications.